Enliven Therapeutics (ELVN)
Market Price (5/19/2026): $39.65 | Market Cap: $2.5 BilSector: Health Care | Industry: Biotechnology
Enliven Therapeutics (ELVN)
Market Price (5/19/2026): $39.65Market Cap: $2.5 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -116 Mil Stock price has recently run up significantly12M Rtn12 month market price return is 135% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.2% Key risksELVN key risks include [1] intense competition for its lead product candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -116 Mil |
| Stock price has recently run up significantly12M Rtn12 month market price return is 135% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.2% |
| Key risksELVN key risks include [1] intense competition for its lead product candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Enliven Therapeutics (ELVN) stock has gained about 50% since 1/31/2026 because of the following key factors:
1. Positive clinical trial data for ELVN-001 in Chronic Myeloid Leukemia (CML) reinforced its potential and progress towards pivotal trials. In January 2026, Enliven announced positive initial Phase 1b data for ELVN-001, highlighting its potential as a best-in-class ATP-competitive inhibitor in CML. This data included a cumulative major molecular response (MMR) rate of 69% by 24 weeks in randomized Phase 1b cohorts, with 53% of patients achieving MMR by 24 weeks as of a December 22, 2025, cutoff date (reported January 8, 2026). Further positive data from the Phase 1 ENABLE trial, demonstrating robust anti-CML activity and a favorable tolerability profile in heavily pretreated patients, was announced in May 2026 and accepted for an oral presentation at the EHA 2026 Congress. The company also confirmed its plan to initiate a Phase 3 pivotal trial for ELVN-001 in the second half of 2026.
2. The company reported a strong financial position and extended cash runway, along with better-than-expected Q1 2026 earnings. As of March 31, 2026, Enliven held $452.4 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into the first half of 2029. For the first quarter of 2026, reported on May 7, 2026, Enliven posted an earnings per share (EPS) of -$0.38, exceeding analysts' expectations of -$0.42 by 9.52%, and narrowing its net loss to $23.6 million compared to $28.5 million in the same period last year.
Show more
1. Positive clinical trial data for ELVN-001 in Chronic Myeloid Leukemia (CML) reinforced its potential and progress towards pivotal trials. In January 2026, Enliven announced positive initial Phase 1b data for ELVN-001, highlighting its potential as a best-in-class ATP-competitive inhibitor in CML. This data included a cumulative major molecular response (MMR) rate of 69% by 24 weeks in randomized Phase 1b cohorts, with 53% of patients achieving MMR by 24 weeks as of a December 22, 2025, cutoff date (reported January 8, 2026). Further positive data from the Phase 1 ENABLE trial, demonstrating robust anti-CML activity and a favorable tolerability profile in heavily pretreated patients, was announced in May 2026 and accepted for an oral presentation at the EHA 2026 Congress. The company also confirmed its plan to initiate a Phase 3 pivotal trial for ELVN-001 in the second half of 2026.
2. The company reported a strong financial position and extended cash runway, along with better-than-expected Q1 2026 earnings. As of March 31, 2026, Enliven held $452.4 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into the first half of 2029. For the first quarter of 2026, reported on May 7, 2026, Enliven posted an earnings per share (EPS) of -$0.38, exceeding analysts' expectations of -$0.42 by 9.52%, and narrowing its net loss to $23.6 million compared to $28.5 million in the same period last year.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 49.8% change in ELVN stock from 1/31/2026 to 5/18/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5182026 | Change |
|---|---|---|---|
| Stock Price ($) | 26.45 | 39.63 | 49.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 62 | 63 | -1.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/18/2026| Return | Correlation | |
|---|---|---|
| ELVN | 49.8% | |
| Market (SPY) | 7.0% | 26.1% |
| Sector (XLV) | -5.4% | 33.5% |
Fundamental Drivers
The 69.2% change in ELVN stock from 10/31/2025 to 5/18/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 5182026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.42 | 39.63 | 69.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 52 | 63 | -17.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/18/2026| Return | Correlation | |
|---|---|---|
| ELVN | 69.2% | |
| Market (SPY) | 8.9% | 18.1% |
| Sector (XLV) | 1.9% | 12.2% |
Fundamental Drivers
The 109.2% change in ELVN stock from 4/30/2025 to 5/18/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5182026 | Change |
|---|---|---|---|
| Stock Price ($) | 18.94 | 39.63 | 109.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 50 | 63 | -20.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/18/2026| Return | Correlation | |
|---|---|---|
| ELVN | 109.2% | |
| Market (SPY) | 34.7% | 18.6% |
| Sector (XLV) | 5.6% | 11.4% |
Fundamental Drivers
The 108.1% change in ELVN stock from 4/30/2023 to 5/18/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5182026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.04 | 39.63 | 108.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 41 | 63 | -34.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/18/2026| Return | Correlation | |
|---|---|---|
| ELVN | 108.1% | |
| Market (SPY) | 84.5% | 27.9% |
| Sector (XLV) | 14.7% | 21.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ELVN Return | -90% | 82% | 238% | 63% | -32% | 168% | 87% |
| Peers Return | -7% | 32% | 41% | -1% | 2% | 9% | 89% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| ELVN Win Rate | 8% | 50% | 42% | 67% | 33% | 100% | |
| Peers Win Rate | 42% | 67% | 58% | 50% | 67% | 51% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| ELVN Max Drawdown | -91% | -59% | -58% | -35% | -39% | -18% | |
| Peers Max Drawdown | -27% | -19% | -12% | -23% | -29% | -23% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ALPS, AVLN, DFTX, EIKN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/18/2026 (YTD)
How Low Can It Go
| Event | ELVN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.9% | -18.8% |
| % Gain to Breakeven | 46.9% | 23.1% |
| Time to Breakeven | 55 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -44.6% | -9.5% |
| % Gain to Breakeven | 80.7% | 10.5% |
| Time to Breakeven | 99 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -58.9% | -24.5% |
| % Gain to Breakeven | 143.4% | 32.4% |
| Time to Breakeven | 156 days | 427 days |
In The Past
Enliven Therapeutics's stock fell -31.9% during the 2025 US Tariff Shock. Such a loss loss requires a 46.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ELVN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.9% | -18.8% |
| % Gain to Breakeven | 46.9% | 23.1% |
| Time to Breakeven | 55 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -44.6% | -9.5% |
| % Gain to Breakeven | 80.7% | 10.5% |
| Time to Breakeven | 99 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -58.9% | -24.5% |
| % Gain to Breakeven | 143.4% | 32.4% |
| Time to Breakeven | 156 days | 427 days |
In The Past
Enliven Therapeutics's stock fell -31.9% during the 2025 US Tariff Shock. Such a loss loss requires a 46.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Enliven Therapeutics (ELVN)
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
AI Analysis | Feedback
1. The Amgen or AstraZeneca of early-stage cancer drug development.
2. A startup Bristol Myers Squibb or Merck focused on pioneering new cancer therapies.
3. An Eli Lilly or Pfizer that's just starting to build its cancer drug pipeline.
AI Analysis | Feedback
```html- ELVN-001: A small molecule inhibitor undergoing Phase 1 clinical trials for chronic myeloid leukemia.
- ELVN-002: A small molecule inhibitor in Phase 1 clinical trials for cancers with an abnormal HER2 gene.
AI Analysis | Feedback
Enliven Therapeutics, Inc. (ELVN) is a clinical-stage biopharmaceutical company. As described, the company is focused on the discovery and development of small molecule inhibitors for cancer, with its lead candidates, ELVN-001 and ELVN-002, currently in Phase 1 clinical trials.
At this stage of development, Enliven Therapeutics does not have commercial products approved for sale. Therefore, the company does not have major customers that purchase its products. Its operations are funded primarily through investments and, potentially, through research collaborations or grants, rather than product sales to other companies or individuals.
AI Analysis | Feedback
NULLAI Analysis | Feedback
Rick Fair, Chief Executive Officer and Member of the Board of Directors Rick Fair has over 25 years of experience in product development and commercialization, with 20 years spent at large pharmaceutical companies. He most recently served as President and Chief Executive Officer of Bellicum Pharmaceuticals, a clinical-stage biopharmaceutical company. Prior to Bellicum, he spent more than 10 years at Roche/Genentech, where he led the Global Product Strategy Oncology/Hematology group, responsible for a $23 billion portfolio and overseeing the launch of five new therapies across solid and hematologic tumors. He also held leadership positions in market access and marketing at Johnson & Johnson. Benjamin Hohl, Chief Financial Officer and Head of Corporate Development Benjamin Hohl joined Enliven Therapeutics from the Healthcare Investment Banking Group at Goldman Sachs & Co LLC, where he worked as an investment banker for nearly a decade (July 2012 to July 2021). In this role, he advised biopharmaceutical and life sciences management teams and boards, executing a broad range of strategic and financing transactions, including over 50 deals totaling more than $75 billion in M&A, equity, and debt financings. He had previously served as Chief Financial Officer of Former Enliven since August 2021 before the company's merger in February 2023. Sam Kintz, Co-founder and Head of Pipeline Sam Kintz is a co-founder of Enliven Therapeutics and previously served as its Chief Executive Officer. Prior to co-founding Enliven, he was an Executive Director of Research at AbbVie and Head of Research at AbbVie Stemcentrx. He also held the position of Vice President, Business Development and Applications, at Biodesy, a biotech startup. His experience includes working at Roche Venture Fund, where he identified and evaluated investment opportunities in the life sciences industry, and as a medicinal chemist at Genentech. Enliven Therapeutics was initially backed by seed capital from OrbiMed and 5AM Ventures, and later secured Series A financing that included Roche Venture Fund, indicating a pattern of involvement with companies supported by private equity and venture capital firms. Joseph P. Lyssikatos, Co-founder and Chief Scientific Officer Joseph P. Lyssikatos is a co-founder of Enliven Therapeutics and serves as its Chief Scientific Officer. Before co-founding Enliven, he was the Vice President of Medicinal Chemistry and DMPK at Biogen. His career also includes roles as an Executive Director at AbbVie, Staff Scientist at Genentech, and Senior Director at Array Biopharma, starting his pharmaceutical career as a medicinal chemist at Pfizer Groton. He has contributed to over 30 programs, leading to the discovery of more than 15 clinical candidates, including four FDA-approved cancer therapies: Koselugo (selumetinib), Mektovi (binimetinib), Tukysa (tucatinib), and Retevmo (selpercatinib). Anish Patel, Co-founder and Chief Operating Officer Anish Patel is a co-founder and the Chief Operating Officer of Enliven Therapeutics.AI Analysis | Feedback
The key risks to Enliven Therapeutics (ELVN) primarily stem from its nature as a clinical-stage biopharmaceutical company focused on drug development.
- Clinical Trial and Regulatory Risk: As a clinical-stage company, Enliven Therapeutics' success is highly dependent on its drug candidates, particularly ELVN-001 and ELVN-002, successfully progressing through clinical trials and ultimately receiving regulatory approval. The company is "heavily dependent on its lead candidate ELVN-001 for BCR-ABL, with significant clinical trial risks and regulatory uncertainties." There is a considerable "risk of failing to demonstrate safety and efficacy of product candidates", and even if trials are successful, there is "regulatory uncertainty" regarding obtaining approvals. This risk is inherent in the biopharmaceutical industry, where drug candidates often fail in various stages of development.
- Financial Sustainability and Need for Additional Funding: Enliven Therapeutics has consistently operated at a loss, with a significant accumulated deficit, reflecting the substantial investments required for pharmaceutical development. "ELVN's financial position reflects substantial investment in R&D, with a need for additional funding to sustain operations." The company's "financial health is a concern, as evidenced by its significant net losses and negative cash flows." To continue advancing its product candidates through clinical trials and toward commercialization, Enliven Therapeutics will likely need to secure additional capital, which could dilute existing shareholders.
- Competition: The pharmaceutical industry is highly competitive, with numerous established companies and emerging biotech firms vying for market share. Enliven Therapeutics "faces competition from companies with greater financial resources and market presence." Competitors could develop more effective or affordable therapies, achieve regulatory approvals more quickly, or establish strong market positions before Enliven Therapeutics can commercialize its own products.
AI Analysis | Feedback
nullAI Analysis | Feedback
Enliven Therapeutics' main products, ELVN-001 and ELVN-002, target specific cancer markets with the following addressable market sizes:
-
ELVN-001 (Chronic Myeloid Leukemia): The global chronic myeloid leukemia (CML) treatment market was valued at approximately USD 8.59 billion in 2023 and is projected to reach USD 16.33 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.4%. Another estimate for the global CML treatment market indicates a value of USD 8.6 billion in 2023, with a projection to reach USD 14.3 billion by 2033, growing at a CAGR of 5.2%. For the 7 major markets (7MM), which include the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan, the CML market reached USD 5.7 billion in 2024 and is expected to grow to USD 8.9 billion by 2035.
-
ELVN-002 (Cancers harboring an abnormal HER2 gene): This product targets HER2+ and HER2 mutant tumors, including HER2-positive breast cancer and HER2+ gastric cancer.
- For the global HER2-positive breast cancer treatment market, it was valued at USD 10.95 billion in 2025 and is projected to reach USD 13.79 billion by 2031, with a CAGR of 3.92%. The 7 major markets (7MM) for metastatic HER2-Positive breast cancer were valued at USD 2,711.6 million in 2024 and are anticipated to reach USD 3,108.1 million by 2035.
- For HER2+ gastric cancer (including GEJ) in the 7 major markets (7MM), the total market size was approximately USD 700 million in 2024 and is projected to increase through 2034.
AI Analysis | Feedback
Enliven Therapeutics (ELVN), a clinical-stage biopharmaceutical company, is focused on the discovery and development of small molecule inhibitors for cancer. Given its current stage of development, expected revenue growth over the next 2-3 years will primarily be driven by key pipeline advancements and strategic activities rather than product sales.
Here are 3-5 expected drivers of Enliven Therapeutics' future revenue growth:
- Advancement of ELVN-001 through pivotal clinical trials: A significant driver for future revenue growth is the successful progression and initiation of the Phase 3 ENABLE-2 pivotal trial for ELVN-001 in chronic myeloid leukemia (CML), which is planned for the second half of 2026. Positive initial Phase 1b data for ELVN-001 has already been reported, and continued successful clinical development will be critical to its potential commercialization.
- Positive clinical data readouts for ELVN-001: Ongoing positive data readouts from the ENABLE trial for ELVN-001 throughout 2026, especially as it advances into later-stage studies, will bolster its market potential and attract further investment or partnerships.
- Strategic partnerships and licensing agreements: As a clinical-stage company, Enliven Therapeutics may generate future revenue through strategic collaborations, licensing agreements, and partnerships. These could include upfront payments, development milestone payments, and future royalties from ELVN-001 or other pipeline candidates. The company is actively evaluating strategic collaborations to accelerate development timelines or maximize commercial value.
- Potential for expedited regulatory pathways and market entry for ELVN-001: ELVN-001 has received Orphan Drug Designation for CML, and the company intends to engage with regulatory authorities to discuss potential expedited approval pathways. A faster path to market, should the clinical data support it and regulators agree, would accelerate the timeline for commercialization and subsequent revenue generation.
AI Analysis | Feedback
Share Issuance
- Enliven Therapeutics completed a $200 million equity raise in June 2025, which included the sale of new shares and warrants.
- A stock sale in 2025 grossed approximately $230 million in proceeds, contributing to the company's cash reserves.
- The weighted-average shares outstanding, basic and diluted, increased from 49.858 million in the fourth quarter of 2024 to 62.213 million in the fourth quarter of 2025.
Inbound Investments
- Enliven Therapeutics closed a $200 million equity raise in June 2025.
- In August 2024, the company received a $10 million milestone payment from Cardurion as per an asset purchase agreement established prior to the merger between Imara Inc. and Enliven Inc.
Capital Expenditures
- While specific capital expenditure figures for property, plant, and equipment are not detailed, the company's significant investment is in research and development.
- Research and development expenses for the full year 2025 totaled $85.9 million, an increase from $80.8 million in 2024 and $64.6 million in 2023.
- These expenses are primarily focused on advancing its pipeline of small molecule kinase inhibitors, including ELVN-001 for chronic myeloid leukemia and ELVN-002 for cancers with an abnormal HER2 gene.
Latest Trefis Analyses
Trade Ideas
Select ideas related to ELVN.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 23.55 |
| Mkt Cap | 2.4 |
| Rev LTM | 0 |
| Op Inc LTM | -155 |
| FCF LTM | -105 |
| FCF 3Y Avg | -68 |
| CFO LTM | -105 |
| CFO 3Y Avg | -68 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.1% |
| Rev Chg 3Y Avg | 9.9% |
| Rev Chg Q | 7.8% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | -5.0% |
| Op Inc Chg 3Y Avg | -41.2% |
| Op Mgn LTM | 38.2% |
| Op Mgn 3Y Avg | 24.1% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 34.7% |
| CFO/Rev 3Y Avg | 21.5% |
| FCF/Rev LTM | 30.4% |
| FCF/Rev 3Y Avg | 17.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.4 |
| P/S | 9.1 |
| P/Op Inc | -6.4 |
| P/EBIT | -5.5 |
| P/E | -5.4 |
| P/CFO | -8.6 |
| Total Yield | -7.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -2.2% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -9.7% |
| 3M Rtn | -7.6% |
| 6M Rtn | -2.2% |
| 12M Rtn | -5.1% |
| 3Y Rtn | 9.0% |
| 1M Excs Rtn | -13.6% |
| 3M Excs Rtn | -15.2% |
| 6M Excs Rtn | 0.0% |
| 12M Excs Rtn | -29.7% |
| 3Y Excs Rtn | -71.8% |
Price Behavior
Price Behavior
| Market Price | $39.63 | |
| Market Cap ($ Bil) | 2.5 | |
| First Trading Date | 03/12/2020 | |
| Distance from 52W High | -17.6% | |
| 50 Days | 200 Days | |
| DMA Price | $39.04 | $26.00 |
| DMA Trend | up | up |
| Distance from DMA | 1.5% | 52.4% |
| 3M | 1YR | |
| Volatility | 66.1% | 83.4% |
| Downside Capture | 71.44 | 87.33 |
| Upside Capture | 196.28 | 166.24 |
| Correlation (SPY) | 19.2% | 18.4% |
ELVN Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.21 | 1.03 | 1.27 | 1.30 | 1.27 | 1.43 |
| Up Beta | -0.13 | -0.22 | 0.93 | 2.13 | 1.44 | 1.29 |
| Down Beta | -0.83 | -0.06 | 0.53 | 2.66 | 1.12 | 1.43 |
| Up Capture | 212% | 331% | 329% | 165% | 225% | 429% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 10 | 21 | 33 | 63 | 125 | 364 |
| Down Capture | 487% | 70% | 35% | -22% | 91% | 109% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 12 | 22 | 31 | 62 | 126 | 387 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELVN | |
|---|---|---|---|---|
| ELVN | 135.1% | 83.3% | 1.36 | - |
| Sector ETF (XLV) | 13.7% | 14.8% | 0.66 | 14.1% |
| Equity (SPY) | 26.7% | 12.1% | 1.66 | 17.8% |
| Gold (GLD) | 40.7% | 26.8% | 1.25 | 4.7% |
| Commodities (DBC) | 47.8% | 18.5% | 1.97 | -2.0% |
| Real Estate (VNQ) | 10.8% | 13.4% | 0.52 | 14.1% |
| Bitcoin (BTCUSD) | -23.9% | 41.9% | -0.54 | 12.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELVN | |
|---|---|---|---|---|
| ELVN | 5.1% | 85.6% | 0.41 | - |
| Sector ETF (XLV) | 5.2% | 14.6% | 0.17 | 16.4% |
| Equity (SPY) | 13.8% | 17.1% | 0.64 | 21.4% |
| Gold (GLD) | 19.5% | 17.9% | 0.88 | 4.8% |
| Commodities (DBC) | 10.8% | 19.4% | 0.44 | 4.0% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 18.2% |
| Bitcoin (BTCUSD) | 6.9% | 55.9% | 0.34 | 10.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELVN | |
|---|---|---|---|---|
| ELVN | -4.4% | 88.0% | 0.29 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.46 | 13.1% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 17.2% |
| Gold (GLD) | 13.2% | 15.9% | 0.69 | 4.2% |
| Commodities (DBC) | 8.6% | 17.9% | 0.39 | 5.0% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.21 | 14.1% |
| Bitcoin (BTCUSD) | 67.3% | 66.9% | 1.06 | 7.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/3/2026 | 4.3% | 5.2% | 31.4% |
| 11/12/2025 | -0.1% | 8.9% | -15.4% |
| 8/13/2025 | -1.1% | -1.6% | -0.1% |
| 3/13/2025 | 2.2% | 3.1% | -18.6% |
| 11/13/2024 | -3.4% | -1.4% | -10.3% |
| 8/13/2024 | 1.3% | 3.6% | 3.8% |
| 3/14/2024 | 3.7% | 56.5% | 72.8% |
| 11/9/2023 | -1.5% | -9.8% | -5.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 7 |
| # Negative | 8 | 8 | 10 |
| Median Positive | 2.2% | 8.9% | 31.4% |
| Median Negative | -1.8% | -5.6% | -14.9% |
| Max Positive | 9.7% | 56.5% | 108.5% |
| Max Negative | -19.0% | -21.4% | -35.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/14/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2029 Cash Runway | 2,030 | 0.0% | Affirmed | Guidance: 2,029 for 2029 | |||
Prior: Q4 2025 Earnings Reported 3/3/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2029 Cash Runway | 2,029 | ||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 4212026 | 47.67 | 5,000 | 238,352 | 1,191,762 | Form |
| 2 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 3272026 | 35.10 | 40,000 | 1,404,024 | 877,515 | Form |
| 3 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 3192026 | 27.76 | 5,000 | 138,800 | 694,000 | Form |
| 4 | Hohl, Benjamin | CHIEF FINANCIAL OFFICER | Direct | Sell | 3102026 | 29.58 | 10,000 | 295,839 | 1,508,779 | Form |
| 5 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 2192026 | 26.17 | 45,000 | 1,177,862 | 654,368 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.